1. Home
  2. BCDA vs STRR Comparison

BCDA vs STRR Comparison

Compare BCDA & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • STRR
  • Stock Information
  • Founded
  • BCDA N/A
  • STRR 1985
  • Country
  • BCDA United States
  • STRR United States
  • Employees
  • BCDA N/A
  • STRR N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • BCDA Health Care
  • STRR Health Care
  • Exchange
  • BCDA Nasdaq
  • STRR Nasdaq
  • Market Cap
  • BCDA 11.0M
  • STRR 6.3M
  • IPO Year
  • BCDA N/A
  • STRR N/A
  • Fundamental
  • Price
  • BCDA $1.99
  • STRR $2.00
  • Analyst Decision
  • BCDA Strong Buy
  • STRR Strong Buy
  • Analyst Count
  • BCDA 1
  • STRR 1
  • Target Price
  • BCDA $25.00
  • STRR $5.00
  • AVG Volume (30 Days)
  • BCDA 51.3K
  • STRR 21.4K
  • Earning Date
  • BCDA 08-12-2025
  • STRR 08-12-2025
  • Dividend Yield
  • BCDA N/A
  • STRR N/A
  • EPS Growth
  • BCDA N/A
  • STRR N/A
  • EPS
  • BCDA N/A
  • STRR N/A
  • Revenue
  • BCDA $3,000.00
  • STRR $57,165,000.00
  • Revenue This Year
  • BCDA N/A
  • STRR $33.64
  • Revenue Next Year
  • BCDA N/A
  • STRR $22.87
  • P/E Ratio
  • BCDA N/A
  • STRR N/A
  • Revenue Growth
  • BCDA N/A
  • STRR 34.33
  • 52 Week Low
  • BCDA $1.63
  • STRR $1.72
  • 52 Week High
  • BCDA $4.66
  • STRR $5.35
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 51.13
  • STRR 45.82
  • Support Level
  • BCDA $1.98
  • STRR $1.95
  • Resistance Level
  • BCDA $2.45
  • STRR $2.02
  • Average True Range (ATR)
  • BCDA 0.17
  • STRR 0.07
  • MACD
  • BCDA 0.01
  • STRR -0.00
  • Stochastic Oscillator
  • BCDA 53.19
  • STRR 36.84

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About STRR Star Equity Holdings Inc.

Star Equity Holdings Inc is a multi-industry diversified holding company. It operates in two segments: Building Solutions segment, through KBS, EBGL and TT, it services residential and commercial construction projects by manufacturing modular housing units, structural wall panels, permanent wood foundation systems, other engineered wood products, and supply general contractors with building materials; and Investments segment, which holds corporate-owned real estate, currently includes one manufacturing facility and the equipment for another manufacturing facility in Maine that it leases back to KBS and its manufacturing facility in Wisconsin that it leases back to TT. The company derives maximum revenue from Building Solutions Segment.

Share on Social Networks: